#esmo21 highlights on gemcitabine vs mfolfirinox in resected pancreatic cancer: prodige 24/cctg pa6
Published 3 years ago • 2.1K plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
1:46
prodige 24- adjuvant #gemcitabine versus modified folfirinox in resected #pancreaticcancer
-
3:59
adjuvant mfolfirinox shows benefits over gemcitabine in pancreatic cancer | thierry conroy
-
1:11
dr. ramanathan on gemcitabine/nab-paclitaxel followed by mfolfirinox in pancreatic cancer
-
0:36
advances in the treatment of pancreatic cancer
-
1:30
gemcitabine and complementary treatments for cancer
-
4:24
espac-4: phase iii trial of combination gemcitabine and capecitabine vs. gemcitabine...
-
1:12
nab-paclitaxel and gemcitabine in soft tissue sarcoma: trial update
-
3:03
gap study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer
-
1:57
the protein rrp9 promotes gemcitabine resistance in pancreatic cancer by activating the akt pathway
-
1:21
esmo essentials for clinicians: gastrointestinal tract tumours - 2nd edition
-
1:38
nepafox: adjuvant gemcitabine vs. folfirinox in resectable pancreatic cancer
-
0:49
evaluating the future role of vegf inhibitors in pancreatic cancer
-
0:33
keynote-966: pembrolizumab gem/cis vs gemc/cis alone in advanced biliary tract cancer
-
0:59
dr. katsuhiko uesaka compares adjuvant s-1 to gemcitabine in pancreatic cancer
-
0:39
types of pancreatic cancer explained : knowing the different forms | dr vivek sukumar
-
0:44
highlights in skin cancer at esmo 2022
-
2:51
#esmo21 highlights on adagrasib in patients with krasg12c-mutated crc: the krystal-1 study
-
0:21
treatment for pancreatic malignancy.
-
1:48
pancreatic cancer: moving forward